I have great fun & satisfaction mentoring @IU_Health residents interested in #retina & #research. Congrats to these fantastic current & prior IU residents for this recent publication on a most-feared complication of #eye surgery:https://t.co/5juDSOKEov Source by Thomas Ciulla, MD, MBA Return to main website.

RT @ThomasCiullaMD: Our study has generated much interest in #Luxturna #genetherapy #healtheconomics: Cost-effectiveness of Voretigene Nepa… Source by Thomas Ciulla, MD, MBA Return to main website.

RT @ThomasCiullaMD: Honored to be interviewed by Dr. Wykoff of Retina Synthesis, on the journey through disruptive retina innovation in aca… Source by Thomas Ciulla, MD, MBA Return to main website.

RT @pharminews: Arctic Vision obtains the first IND approval for the treatment of UME in China, Suprachoroidal space (SCS) injection potent… Source by Thomas Ciulla, MD, MBA Return to main website.

Just published: Suprachoroidal DNA nanoparticle genetherapy preclinical study: https://t.co/XSE6Pydjjm Suprachoroidally Delivered DNA Nanoparticles Transfect Retina and Retinal Pigment Epithelium/Choroid in Rabbits | TVST | ARVO Journals #retina #suprachoroidal #GeneTherapy https://t.co/ERRLCc7Jd2 Source by Thomas Ciulla, MD, MBA Return to main website.

Honored to be interviewed by Dr. Wykoff of Retina Synthesis, on the journey through disruptive retina innovation in academia, clinical practice and industry… #retina #biotech #genetherapy https://t.co/LYP417LVx0 via @YouTube Source by Thomas Ciulla, MD, MBA Return to main website.

For COVID-19, mRNA vaccines have sprinted to approval. Historically, #retina played an important role in #RNA #therapy development, with the first approved ASO in 1998. We just published on potential RNA therapies for #AMD, #diabeticretinopathy & IRDs… https://t.co/S9TpaLYBsg Source by Thomas Ciulla, MD, MBA Return …